Cadila Healthcare, one of the leading pharmaceutical companies, has announced that the company's Topical manufacturing facility located at Changodar, Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA following the inspection carried out in March 2016.

The receipt of EIR indicates the successful closure of the inspection points (483s) raised.

The topical plant is a dedicated facility for manufacturing ointments and does not form a part of the Moraiya formulations manufacturing plant.

Shares of the company declined Rs 2.55, or 0.69%, to trade at  Rs 366.60.  The total volume of shares traded  was  117,139 at the BSE (10.43 a.m., Tuesday).